---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004062"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T23:11:09.073428+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics stockholders approve 475,000-share increase in incentive plan

## Summary
- Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.
- All three Class II director nominees elected: Blanchard, Capper, Larsen.
- Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.
- Deloitte & Touche ratified as independent auditor for fiscal 2025.
- Annual meeting had 86.13% of voting power present; no opposition to board's solicitation.

## SEC filing metadata
- accession: 0001171843-25-004062
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/0001171843-25-004062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325004062/f8k_062425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004062
- JSON: https://secwatch.observer/filing/0001171843-25-004062.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.